Clinical OMICS

MAY-JUN 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 40 of 51 May/June 2018 Clinical OMICs 39 Massively Parallel Profiling of Single-Cell Genomes The Chromium Single Cell CNV Solution is a scalable and easy-to-use technology for rapid and massively parallel profiling of single-cell genomes. This solution is the first to be built on the company's new technology advancement for generating Cell Beads and Gel Beads (CBGBs). Chromium Single Cell CNV Solution profiles the genomes of individual cells to reveal tumor heterogeneity, characterize somatic mosaicism of neurons, and authenticate cell line identity and clonal purity. The solution also includes a comprehensive software suite from 10x Genomics to rapidly analyze and visualize large single-cell CNV experiments. The Cell Ranger DNA analysis pipeline provides a turnkey solution for single-cell CNV calling and clustering. The Loupe scDNA Browser provides an easy-to-use tool for inspecting and interrogating genomic regions and cell clusters. 10x Genomics New Products Research Kits to Identify Breath-Based Biomarkers Owlstone Medical has introduced Breath Biopsy Kits, based on the com- pany's proprietary Breath Biopsy plat- form. The kits allow academic, clinical, and pharmaceutical researchers to discover and validate breath-based biomarkers in early detection and precision medicine research. Breath Biopsy Collection Kits enable researchers to collect reliable breath samples that can then be analyzed in their own laboratory using instrumentation such as the Lonestar VOC Analyzer. Breath Biopsy Discovery VOC Kits include the consumables required for breath collection, as well as a comprehensive global breath VOC analysis performed in Owlstone Medical's Breath Biopsy Services Labora- tory. The kits contain consumables for use with the ReCIVA Breath Sampler including a Breath Biopsy Cartridge to collect, stabilize and enrich VOCs in breath, enhancing the sensitivity for detection of VOCs, and a disposable Breath Biopsy Mask. Owlstone Medical Integrated Metabolic Analysis and Imaging Platform Agilent Technologies and BioTek Instruments have created an integrated solution that combines cellular metabolic analysis and imaging technologies. The solution integrates the Agilent Seahorse XFe96/XFe24 Analyzers with the BioTek Cytation 1 Cell Imaging Multi-Mode Reader to create a standardized approach for comparing XF datasets. It improves assay workflow, embeds images into WAVE software, and applies normalization values to Seahorse XF measurements. With the Agilent Seahorse XF WAVE software researchers can toggle between XF data, brightfield im- ages, and fluorescence images in a unified software experience. The Agilent Seahorse XFe Analyzers simultaneously measure the two-major cellular energy-producing pathways—mitochondrial respiration and glycolysis—in live cells, in real time. The BioTek Cytation 1 Cell Imaging Multi-Mode Reader is con- figurable for fluorescence and high contrast bright- field cellular imaging with up to 60x magnification. Agilent Technologies and BioTek Instruments Liquid Biopsy Kits for Prostate and Lung Cancer Qiagen has launched two novel liquid biopsy panels to evaluate circulating tumor cells (CTCs) in the growing field of research into molecular mechanisms in prostate and lung cancers. The AdnaT- est ProstateCancerPanel AR-V7 Kit provides insights into tumor biology by detecting the androgen receptor splice variant 7 in CTCs of prostate tumor origin isolated from blood samples to investigate potential resistance to drugs for advanced prostate cancer. The test is licensed from Johns Hopkins University for nucleic acid detection of the AR-V7 biomarker. The AdnaTest LungCancer Kit delivers unique insights into the molecular mechanisms of lung cancer through highly specific selection of CTCs, including stem cell–like cells implicated in cancer growth and epithelial–mesenchymal tran- sition (EMT), an important marker of resistance to cancer therapy. A proprietary set of antibodies provides sensitive detection of lung cancer-associated targets through reverse-transcriptase PCR. Qiagen

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAY-JUN 2018